Equities

GlaxoSmithKline Pharmaceuticals Ltd

GlaxoSmithKline Pharmaceuticals Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)2,698.35
  • Today's Change-87.65 / -3.15%
  • Shares traded76.78k
  • 1 Year change+69.18%
  • Beta0.4621
Data delayed at least 15 minutes, as of Sep 19 2024 11:15 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments18,56816,54128,309
Total Receivables, Net3,7203,4193,052
Total Inventory5,2504,6005,347
Prepaid expenses206150139
Other current assets, total239233234
Total current assets27,98424,94337,080
Property, plant & equipment, net3,1073,1513,254
Goodwill, net------
Intangibles, net236341345
Long term investments9.451112
Note receivable - long term2,3133,0224,071
Other long term assets423415328
Total assets35,56633,26646,333
LIABILITIES
Accounts payable6,2544,2785,705
Accrued expenses1,1429471,031
Notes payable/short-term debt000
Current portion long-term debt/capital leases122121125
Other current liabilities, total7,7317,91810,123
Total current liabilities15,24913,26416,984
Total long term debt653576
Total debt187155201
Deferred income tax------
Minority interest------
Other liabilities, total2,4762,5552,643
Total liabilities17,79015,85319,703
SHAREHOLDERS EQUITY
Common stock1,6941,6941,694
Additional paid-in capital------
Retained earnings (accumulated deficit)16,08215,71924,935
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity17,77617,41326,630
Total liabilities & shareholders' equity35,56633,26646,333
Total common shares outstanding169169169
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.